Search global stocks & ETFs...Ctrl K
Learn Mode
GRAL
Stock Profile
08-10
Recommended Metric
Score Card
Explore Scores Tab
2.83
Average
Valuation Score
Key Score
2.00
Bad
Management
2.00
Bad
Growth
3.00
Average
Profitability
3.00
Average
Fin. Health
3.00
Average
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$68.95
Baseline
High
$84.00
▲
21.83%
Avg
$68.19
▼
-1.10%
Low
$56.56
▼
-17.97%
Analyst Ratings based on 14 Analysts
Strong Buy
429%
Buy
536%
Hold
536%
Sell
000%
Strong Sell
000%
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.Read More